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Comparison of Nasal Nitric Oxide
Levels between the Inferior
Turbinate Surface and the Middle
Meatus in Patients with Symptomatic
Allergic Rhinitis
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Takashi Ishino1 and Katsuhiro Hirakawa1
ABSTRACT
Background: Because of the anatomical complexity and the high output of the human nose, it has been un-
clear whether nasal nitric oxide (NO) serves as a reliable marker of allergic rhinitis (AR). We examined whether
nasal NO levels in the inferior turbinate (IT) surface and the middle meatus (MM) differ in symptomatic AR pa-
tients.
Methods: We measured fractional exhaled NO (FeNO) and nasal NO in normal subjects (n = 50) and AR pa-
tients with mild symptoms (n = 16) or moderate or severe symptoms (n = 27). Nasal NO measurements were
obtained using an electrochemical analyzer connected to a catheter and an air-suction pump (flow rate 50 mL
sec).
Results: Compared to the normal subjects, the AR patients showed significantly higher nasal FeNO and nasal
NO levels in the IT area. No significant difference in the MM area was observed among the three groups. The
MM area showed higher NO levels than the IT area in all three groups. The ratio of nasal NO levels of the MM
area to the IT area (MMIT ratio) was significantly lower in the AR groups. The moderatesevere AR patients
showed significantly higher nasal NO in the IT area (104.4 vs. 66.2 ppb) and lower MMIT ratios than those in
the mild AR patients. The analysis of nasal brushing cells revealed significantly higher eosinophil cationic pro-
tein and nitrotyrosine levels in the AR groups.
Conclusions: Nasal NO assessment in the IT area directly reflects persistent eosinophilic inflammation and
may be a valid marker to estimate the severity of AR.
KEY WORDS
allergic rhinitis, exhaled nitric oxide, inferior turbinate, nasal nitric oxide, nitrotyrosine
ABBREVIATIONS
AR, allergic rhinitis; ECP, eosinophil cationic protein; FeNO, fractional exhaled nitric oxide; IT, inferior turbinate;
MM, middle meatus; NO, nitric oxide; NT, nitrotyrosine; NOS, nitric oxide synthase; ppb, parts per billion.
INTRODUCTION
The standardization of measuring techniques by the
American Thoracic SocietyEuropean Respiratory So-
ciety (ATSERS) has opened the way for the collec-
tion of comparable airway data on nitric oxide (NO)
in normal subjects and those with disease states.1,2
Allergic rhinitis (AR) has been considered to be asso-
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ciated with increased NO levels. However, it has not
yet been determined whether nasal NO serves as a
reliable index of disease severity, or to what extent
NO concentrations inside the nose contribute to pa-
thologies of AR.3-5 Nasal NO is not routinely meas-
ured in daily clinical practice. One reason may be the
heterogeneous results found in previous studies,
mainly due to the complexity of the anatomical and
physiological features of the human nose and the lack
of consensus concerning the suitable measurement
technique.6-8
In the present study, the fractional exhaled nitric
oxide (FeNO) and nasal NO levels were examined in
a population of normal subjects and AR patients. We
used a newly designed method to measure nasal NO
locally based on the anatomical features of the nasal
cavity. For this purpose, the NO analyzer was con-
nected to a suction catheter and a fixed-quantity suc-
tion pump in an out-patient clinic setting. The hand-
held device with an electrochemical sensor for nasal
NO measurement has been shown to be reliable and
simple to use at a lower cost.9,10
Here we examined whether local gradients of NO
concentration in different areas inside the nasal cavity
differ among normal subjects and AR patients classi-
fied by subjective symptom severity. We also ob-
tained nasal brushing cells from the surface of the in-
ferior turbinate mucosa and analyzed the concentra-
tions of the extracted inflammatory mediators related
to eosinophil activation and NO metabolism. We note
that the nasal NO assessment described here is non-
invasive, quickly performed, and may directly reflect
the degree of allergic inflammatory conditions adja-
cent to the surface mucosa of the inferior turbinate.
METHODS
SUBJECTS
Ninety-three subjects were included in this cross-
sectional, between-group and method comparison
study. The subjects were 43 patients with perennial
AR without bronchial asthma (28 males and 15 fe-
males; mean age 27.7 years) and 50 normal volun-
teers without nasal symptoms (30 males and 20 fe-
males; mean age 32.1 years). The AR patients were
recruited on an outpatient setting and subdivided into
two groups based on disease severity: the group of 16
patients with mild symptoms (mild group) and the
group of 27 patients with moderate or severe symp-
toms (moderatesevere group).
The diagnosis of AR was based on clinical history,
the presence of subjective nasal symptoms together
with positive nasal eosinophil tests, and positive skin
reactions or serum allergen-specific IgE antibody
measurements against house dust mites. Nasal endo-
scopy was performed for all subjects before measur-
ing nasal NO in order to assess the degree of nasal
septum deviation and patency of middle meatus, and
to exclude the presence of nasal polyposis. We ex-
cluded current-smokers and patients who had been
treated with any allergen-specific immunotherapy.
The patients did not receive any anti-allergic medica-
tion in the 30 days before the study. The patients’
subjective symptoms were recorded at the time of the
NO measurement. They include the average number
of paroxysmal sneezing, episodes of nose blowing,
and the degree of nasal blockage. The severity of the
disease was then determined as mild, moderate or se-
vere based on the classification proposed by the Japa-
nese guideline for allergic rhinitis.11
The study protocol was approved by the Institu-
tional Review Board at the Hiroshima University
School of Medicine (Project approval #181-1). The
purpose of the research and experimental protocols
was explained to all participants, and written in-
formed consent was obtained prior to the study.
NITRIC OXIDE MEASUREMENTS
The subjects’ NO levels were measured using a hand-
held electrochemical analyzer (NObreathⓇ, Bedfont
Scientific, Rochester, UK) according to the ATSERS
guidelines.1 For the oral FeNO measurements, the
subjects exhaled at a flow rate of 50 mLs through a
mouthpiece assisted by visual cues. For the nasal
FeNO measurements, the subjects were instructed to
exhale transnasally with their mouth closed into a
nose adaptor at the same flow rate, as described.12
The nasal FeNO measurements were carried out for
the right and left nasal cavities separately, with the
other nostril closing in turn. We also measured nasal
NO in all of the subjects by directly aspirating air
from the nasal cavity. For this purpose, the NO ana-
lyzer was connected to a suction catheter via a sterile
syringe filter and a portable air-suction pump (MP-
Σ300N, Sibata Science, Saitama, Japan), which could
be set at constant flow levels (Fig. 1). The aspiration
flow rate was fixed at a rate of 50 mLsec, and the tip
of the catheter was placed inside the nasal cavity un-
der direct vision during the sampling period. Two dif-
ferent target areas were set based on the anatomical
features of the nasal cavity, i.e., near the anterior sur-
face of the inferior turbinate (IT area) and the front of
the middle meatus (MM area). The subjects were ad-
vised to breathe through the mouth with their soft
palate elevated to cease the choanal airflow. Nasal
NO levels were measured separately for the left and
right side, leaving the other nostril open, in align-
ment with ATS recommendations.1 The measure-
ments were performed in the same clinic under con-
stant environmental conditions. The measurement
was repeated three times and the mean value was
used for analysis.
NASAL CELL SAMPLING
Nasal brushing cell specimens were obtained for an
enzyme-linked immunosorbent assay (ELISA) from
27 of the 50 normal subjects and 31 of the 43 AR pa-
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Fig.　1　(a) Confi guration of the nose catheter, silicon tubes, and the air-suction pump used for 
the direct nasal NO measurement. The tip of the catheter was placed (b) in the anterior surface of 
the inferior turbinate (IT) or (c) in front of the middle meatus (MM) during the aspiration period.
tients (10 in the mild group and 21 in the moderate
severe group) who agreed to participate. There was
no artificial bias for patient selection in cell sampling.
A topical decongestant was applied to the nose just af-
ter the completion of the series of NO measurements,
and secretions were carefully removed. Cells were
then obtained by scraping of the medial wall of the IT
under direct vision using a CytobrushⓇ (Medscand
Medical, Malmo, Sweden). The cells were placed im-
mediately in a 2-mL volume of chilled phosphate buff-
ered saline (PBS) and then stored at -80℃ until fur-
ther use. Protein extraction from the cell suspension
was performed by a tissue homogenizer using bead-
beating technology (PrecellysⓇ 24, Bertin Technolo-
gies, Montigny-le-Bretonneux, France) in 2-mL tubes
with 1.4-mm prefilled glass beads (6000 rpm, two cy-
cles for 20 s each).
The concentrations of eosinophil cationic protein
(ECP) and nitrotyrosine (NT) from the supernatant
were measured quantitatively by the ELISA method.
Commercially distributed kits for ECP (ECP ELISA,
Aviscera Bioscience, Santa Clara, CA, USA) and for
NT (OxiSelectTM Nitrotyrosine ELISA Kit, Cell Bio-
labs, San Diego, CA, USA) were used according to
the instructions supplied by the manufacturer.
DATA ANALYSIS
Group data are expressed as means ± standard devia-
tions (SD). For multiple comparisons, a screening of
data for differences was first carried out using the
Kruskal-Wallis test. If the analysis gave a significant
result, a further comparison was done by the Mann-
Whitney U-test for the between-group analysis. The
comparison of paired nasal NO levels between differ-
ent areas was assessed with the Wilcoxon rank sum
test. Spearman rank correlation was used in evaluat-
ing correlations. P-values < 0.05 were considered sig-
nificant.
RESULTS
DIRECT MEASUREMENT OF NASAL NO LEVELS
The demographics and clinical background of the
study population are summarized in Table 1. No sig-
nificant difference between the normal and AR
groups was found in the baseline data of gender or
age distribution. The distribution of the oral and nasal
FeNO values in each group is shown in Figure 2.
Compared to the normal subjects, the patients in both
AR groups showed significantly higher levels of nasal
FeNO. There was no significant difference in nasal
FeNO levels between the mild and the moderatese-
vere AR groups. The AR patients tended to show
higher levels of oral FeNO, but the difference was not
significant. The direct measurement of nasal NO lev-
els from the IT area and the MM area inside the nasal
cavity was successfully achieved using the current
setting for all of the subjects. We had difficulty meas-
uring the nasal NO levels in the MM area of the uni-
lateral side in four normal subjects and three AR pa-
tients because of severe nasal septum deviation.
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Table　1　Demographics and clinical background of the study population
Normal volunteers
AR patients
Mild group Moderate/severe group
number (male/female) 50 (30/20) 16 (11/5) 27 (17/10)
age 32.1 (12.5) 26.1 (5.8) 28.7 (8.4)
subjective nasal symptom score
sneezing - 0.31 (0.47) 1.48 (1.08)
nose blowing - 0.81 (0.4) 2.26 (1.09)
nasal blockage - 0.87 (0.34) 2.44 (1.05)
total score - 2 (0.63) 6.19 (2.76)
Data are shown as mean with standard deviations in parenthesis.
Fig.　2　(a) Oral and (b) nasal FeNO levels in the normal subjects (n = 50) and AR pa-
tients in the mild group (n = 16) and in the moderate/severe group (n = 27). The average 
of right and left nasal cavities was used for the nasal FeNO level of each individual. Error 
bars = mean values and SD. *p < 0.05; **p < 0.01; N.S., no signifi cance; FeNO, fractional 
exhaled nitric oxide.
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Therefore, 96 sides of the nasal cavity in the normal
group and 83 sides in the AR group were processed
for analysis. None of the subjects reported adverse ef-
fects after the procedure.
As shown in Figure 3, the nasal NO levels in the IT
area in both groups of AR patients were significantly
higher than those of the normal subjects. The AR pa-
tients in the moderatesevere group also showed sig-
nificantly higher nasal NO in the IT area compared to
the mild AR patients (104.4 ppb vs. 66.2 ppb). How-
ever, there was no significant difference in nasal NO
levels in the MM area among the three groups. Con-
sequently, the ratio of nasal NO levels of the MM
area to the IT area (MMIT ratio) was significantly
lower in the two AR groups than in the normal group
(Fig. 3c), with the moderatesevere AR group show-
ing significantly lower MMIT ratios compared to the
mild AR group. When the same nasal cavity was com-
pared for each subject, the MM area showed higher
NO levels than the IT area, and the differences were
Nasal Nitric Oxide in Allergic Rhinitis
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Fig.　3　Nasal NO levels (a) in the IT area and (b) in the MM area in the normal subjects and AR patients in the 
mild and moderate/severe groups. (c) The nasal NO ratio of the MM area to the IT area (MM/IT ratio) for each 
group. Measurement of the nasal NO levels and the calculation of the MM/IT ratio were carried out separately for 
the left and right sides of the nose, and the average of the two cavities was used for each individual. Error bars = 
mean values and SD. *p < 0.05; **p < 0.01; N.S., no signifi cance.
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Fig.　4　Correlation between nasal FeNO levels and nasal NO levels (a) in the IT area and (b) in 
the MM area for each nasal cavity in all subjects (n = 179).
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significant in all three groups. The mean differences
in the nasal NO levels in the IT area between the
right and left cavities were 16.1 ppb (SD 21.1) in the
normal group, 18.9 ppb (SD 10.8) in the mild AR
group, and 39.7 ppb (SD 35.7) in the moderatese-
vere AR group. The mean differences in the nasal NO
levels between the cavities were more pronounced in
the MM area: 30.5 ppb (SD 33.8) in the normal
group, 38.5 ppb (SD 42.5) in the mild AR group, and
35.4 ppb (SD 35.1) in the moderatesevere AR group.
The correlations between nasal FeNO levels and na-
sal NO levels in the IT and MM areas for each nasal
cavity are shown in Figure 4. We found positive cor-
relations between the paired two parameters, but the
coefficient was markedly higher for nasal NO in the
IT area than that in the MM area (r = 0.3243 vs. r =
0.1648).
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Fig.　5　Comparison of the levels of (a) ECP and (b) nitrotyrosine in the nasal brushing 
cells. Error bars = mean values and SD. *p < 0.05; **p < 0.01.
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ELISA OF NASAL BRUSHING CELLS
The ELISA of nasal brushing cells revealed elevated
concentrations of ECP derived from activated eosino-
phils and nitrotyrosine from oxidized NO metabolites
in the allergic patients (Fig. 5). The mean ECP level
in the moderatesevere group was significantly
higher than that in the normal subjects. The mean
NT levels in the two AR groups were both signifi-
cantly higher than that in the normal group.
DISCUSSION
Allergic rhinitis has been thought to be associated
with increased NO levels, mainly by the increased in-
ducible nitric oxide synthase (iNOS) expression in
the inferior turbinate mucosa.5,13-15 Several authors
have reported increased nasal NO levels in sympto-
matic AR patients.12,16-20 Conversely, some studies de-
tected no significant differences between AR patients
and control subjects.21-23 These seemingly conflicting
results regarding NO levels may reflect the functional
complexity of NO in the human nose. There is a great
difference in background NO output between the up-
per and the lower airways. In the upper airways,
there is a high background output, and thus an in-
crease (e.g., allergic rhinitis) tends to be obscured,
whereas a decrease (e.g., primary ciliary dyskinesia
or chronic rhinosinusitis with nasal polyps) is usually
easier to reveal.8,24 Although NO production in the
nasal mucosa of AR patients may be up-regulated,
this increase could be counteracted by swelling of the
mucosa and secretions that lead to impaired NO dif-
fusion. In addition, the high background levels of NO
from constitutive sources may blunt smaller in-
creases in mucosal NO output. We hypothesize that
nasal NO is a valid marker for allergic inflammation
and that the measurement of local NO levels based
on the anatomical features of the human nasal cavity
might be useful in distinguishing AR patients from
normal subjects. High nasal NO levels detected in the
IT area in symptomatic AR patients can directly re-
flect the persistence of mucosal eosinophilic inflam-
mation in the inferior turbinate.
In this study, we validated two different methods as
recommended by the ATS to assess the NO level in
the nasal cavity, i.e., nasal FeNO and nasal NO.1 Na-
sal FeNO is considered to represent a fraction of en-
dogenous NO with contaminated air passing through
the nose at a relatively high flow rate.7 The exhalation
process may be influenced by changes in the airflow
physics caused by inter-individual variations in the
anatomical structure of the nasal cavity. As for nasal
NO measurements, most of the previous reports con-
cluded that nasal NO can be measured with fair re-
producibility based on several different approaches
proposed thus far.17,25,26 Qian et al. found no signifi-
cant difference in nasal NO with aspiration flows
ranging from 2.2 to 6.2 Lmin, which is in agreement
with the recommended aspiration by the ATS.27 In
Nasal Nitric Oxide in Allergic Rhinitis
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the present study, the nasal NO measurement was
conducted by direct sampling from one side of the
nose with an airstream of a constant rate of 3 Lmin.
The subjects were instructed to breathe orally with
their soft palates elevated and to block the communi-
cation to the nasal cavity. The method enables us to
avoid possible contamination of exhaled NO derived
from the lower respiratory tract, and the results ob-
tained are immediately available for clinical assess-
ment.
The results of the present study clearly indicate
that increased NO levels near the surface of the infe-
rior turbinate can be a simple and sensitive marker
for the diagnosis of AR. In order to avoid an impact
on the nasal NO results due to a sizable contribution
from the paranasal sinuses, we found it advantageous
to perform the monitoring in this designated area.
The nasal FeNO levels in this study were significantly
different between the AR patients and normal con-
trols. This finding is compatible with our previous
study, although the distribution of nasal FeNO levels
in the present population was shifted slightly lower.12
One possible explanation for this change is that the
nasal FeNO measurements were carried out for the
right and left nasal cavities separately in this study,
whereas transnasal exhalation procedure was done
bilaterally in our previous study. These results seem
to be related to an intimate association between nasal
NO in the IT area and nasal FeNO irrespective of al-
lergic diathesis, suggesting that the aerodynamic dis-
tribution of NO levels in the human nose is a continu-
ous trait.28 However, the discriminative power of na-
sal NO in the IT area in the present study was higher
than that obtained with conventional FeNO measure-
ment techniques. We found that the severity of daily
nasal symptoms in the AR patients was reflected as
an increase in nasal NO levels in the IT area. Al-
though our statistical analysis indicated close correla-
tions between nasal FeNO levels and nasal NO levels
in the IT area, some of the subjects had shown rela-
tively higher nasal NO values in the IT area. The ten-
dency was more pronounced in the moderatesevere
AR patients. The reasons for this phenomenon are
unclear, but several previous studies indicate the
same tendency.4,6 The exhalation process in the mod-
eratesevere AR patients with hypertrophic inferior
turbinates may be influenced by modification of the
nasal airflow in narrowing pathways.
As for the difference in nasal NO between the right
and left nasal cavities, Alexanderson et al. reported
that in 331 normal and symptomatic subjects, the
mean difference in nasal NO between the nostrils was
14 ppb and nearly 95% of the subjects had a difference
of <45 ppb.26 They also found that atopy was signifi-
cantly associated with a high difference of nasal NO
levels between the nostrils. These results are consis-
tent with those of the present study. We also found
that 95.6% (4446) of the normal subjects, 93.3% (14
15) of the mild AR patients, and 68% (1725) of the
moderatesevere AR patients had a difference of <45
ppb in the IT area. These findings indicate that large
differences in nasal NO between the cavities may pre-
dict the presence of not only atopic diathesis but also
an ongoing inflammatory allergic reaction in the infe-
rior turbinate. Another supplementary finding of this
study is that the difference in nasal NO levels be-
tween the IT area and the MM area can also be used
as a marker for AR diagnosis. The MMIT ratio was
significantly lower in the AR group, with the differ-
ences being more significant than the FeNO meas-
urement. However, limited data are available for the
interpretation of the MMIT ratio in the present
study, because we performed the nasal endoscopy
only to evaluate the patency of the middle meatus.
Further studies are necessary for the use of this pa-
rameter to evaluate various nasal diseases (including
AR) in relation to inter-individual differences in ana-
tomical characteristics of the nose.
Nasal NO levels in the MM area have been postu-
lated to depend mainly on the amount of NO pro-
duced by the ciliated epithelium of the paranasal si-
nuses and the size of the paranasal sinus ostia.29 In
the present study, we found that most participants
showed higher NO levels in the MM area than in the
IT area (94.8% of the normal subjects and 74.7% of the
AR patients). By emphasizing the MM area in this
study, we assumed that the maxillary and anterior
ethmoid sinuses are the dominant source of nasal NO
detected in this area. Arnal et al. also found that
symptomatic AR patients exhibited an acute increase
in nasal NO after the administration of a topical vaso-
constrictor, suggesting that acute changes in the wid-
ening of the ostio-meatal complex may affect the
physiological mixing of paranasal sinus NO with that
of the nasal cavity.18 However, since standardized
measurements of sinus NO have not yet been estab-
lished, further studies are required to assess the rela-
tive importance of the volume-surface area of the indi-
vidual sinus in relation to the NO transport to the na-
sal cavity, where it is commonly measured.
The increased NO in allergic rhinitis has several
pathophysiologic consequences, including vasodila-
tion, modification of sensory nerve endings, and accu-
mulation of activated eosinophils. Nitrotyrosine is a
stable downstream product of multiple pathways
formed in the presence of excess NO production and
oxidative stress by the modification of tyrosine resi-
dues.30,31 In patients with severe asthma, the degree
of airway eosinophilia can be predicted by a combina-
tion of FeNO levels, iNOS expression, and NT pro-
duction.32,33 The intranasal administration of eotaxin
to AR patients also induced a significant increase in
nasal NO with accompanying local eosinophil recruit-
ment.34 In the present study, the production of both
ECP and NT was significantly up-regulated in the AR
patients, associated with elevated nasal NO in the IT
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area. These results are in accord with those of these
previous studies, where the NO concentration was
thought to reflect eosinophilic inflammation and auto-
toxic NO metabolisms.
The limitations of this study include its cross-
sectional study design, without ability to see the ef-
fects of therapeutic modalities for each patient. Fur-
ther studies are required to reinforce the usefulness
of nasal NO measurement as an objective method for
assessing the outcome of various anti-allergic thera-
pies.
The on-line method for nasal FeNO and nasal NO
measurements is highly reproducible and easy to per-
form for both the subject and the clinician. Increased
NO levels near the IT surface can be sensitive mark-
ers for the diagnosis of allergic rhinitis, with the sig-
nificance being more prominent than nasal FeNO.
Relatively high nasal NO levels in the MM area also
indicate the role of paranasal sinuses acting as a
physiological NO reservoir in humans. We suggest
that such advances in the standardized measurement
techniques and established guidelines for standard
values will exploit nasal NO for the diagnosis, treat-
ment, and monitoring of relevant upper airway disor-
ders.
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